Prognostic factor could help identify tumor recurrence after surgery for prostate cancer

Slightly more than 10% of all patients who undergo successful surgery for prostate cancer have an elevated risk of tumor recurrence afterwards - especially as metastases. Under the microscope, it is possible to identify invasion of the tumour into the lymph and blood vessels, this being the tumour behaviour responsible for the formation of metastases, so that it can be used as a prognostic factor. This has now been demonstrated by Harun Fajkovic of MedUni Vienna's Department of Urology in a study involving 7,000 patients in "Urologic Oncology". Fajkovic will also report on the latest research findings at the largest international congress on prostate cancer "PROSCA", currently taking place in Vienna.

Lymphovascular invasion (LVI) means that malignant cancer cells "invade" the blood vessels and lymphatic system, from whence they can be transported onwards. "They can implant themselves, for example as micro-metastases in the lung or spine and then slowly replicate to form a new tumour at another site in the body," explains Fajkovic.

Detection of LVI, in combination with other characteristics in the pathological analysis of the resected tumour, therefore acts as a sort of alert, even if the patient's post-operative PSA value, the current marker for prostate cancer, is below the critical limit. Fajkovic: "Patients could then conceivably be offered additional supportive treatment straightaway, for example, radiotherapy or chemotherapy - rather than waiting to see." LVI has also been identified as an independent prognostic factor in other types of cancer, such as breast cancer or bladder cancer.

According to Statistik Austria (status 2013), around 5,000 men in Austria develop prostate cancer (adenocarcinoma) every year. Approximately 1,150 of those affected die over the same period. Prostate cancer is the third commonest male cancer worldwide.

Source: http://www.meduniwien.ac.at

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative urine test could improve pancreatic cancer survival rates